Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

NCT05205161 : A Modular Phase I/II, Open-label, Dose Escalation and Expansion, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AZD0466 as Monotherapy or in Combination With Anticancer Agents in Patients With Advanced Non-Hodgkin Lymphoma.

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Treatment<br/>TrialTypeTreatment
Trial

One/TwoPhase One/Two

18-130Age 18-130

Blood<br/>CancersCancer LocationBlood
Cancers

Treatment | Blood / Myeloma / LymphomaB-Cell Non Hodgkin Lymphoma,Diffuse Large Cell Lymphoma,Follicular Lymphoma,Lymphoma,Mantle Cell Lymphoma

Trial Overview Read MoreRead more

This trial will assess how safe, tolerable and effective a new targeted therapy (AZD0466) is on its own and in combination with other cancer treatments, in people with advanced Non-Hodgkin Lymphoma.
 

This trial is treating patients with Non-Hodgkin Lymphoma.

This is a systemic therapy trial.

You may be able to join this trial if:

  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Modular Phase I/II, Open-label, Dose Escalation and Expansion, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AZD0466 as Monotherapy or in Combination With Anticancer Agents in Patients With Advanced Non-Hodgkin Lymphoma.

Commercial Sponsor

AstraZeneca

Summary

This is a non-randomised, dose escalation and expansion trial, which will be run across two parts. In Part 1 (dose escalation) and Part 2 (dose expansion) all participants will receive treatment with AZD0466 for a maximum period of 2 years or until disease progression, initiation of alternative anticancer treatment, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue study intervention, whichever occurs first. In Part 2, participants will receive AZD0466 treatment at the recommended phase 2 dose determined in Part 1.

Recruiting Hospitals Read MoreRead more

Austin Health
Heidelberg
Ms Samantha Chakar
samantha.chakar@austin.org.au
03 9496 3088

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next